189 related articles for article (PubMed ID: 28440040)
1. Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the National Cancer Database.
Mak KS; Agarwal A; Qureshi MM; Truong MT
Cancer Med; 2017 Jun; 6(6):1192-1200. PubMed ID: 28440040
[TBL] [Abstract][Full Text] [Related]
2. Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: A National Cancer Database Analysis.
Bingham B; Patel CG; Shinohara ET; Attia A
J Neurooncol; 2018 Jan; 136(2):385-394. PubMed ID: 29209874
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival.
Glaser SM; Dohopolski MJ; Balasubramani GK; Flickinger JC; Beriwal S
J Neurooncol; 2017 Aug; 134(1):107-118. PubMed ID: 28527010
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population.
Haque W; Verma V; Butler EB; Teh BS
Am J Clin Oncol; 2018 Feb; 41(2):167-172. PubMed ID: 29369825
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
6. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
7. Improved survival in rectal cancer patients who are treated with long-course versus short-course neoadjuvant radiotherapy: A propensity-matched analysis of the NCDB.
Chapman BC; Goodman K; Hosokawa P; Gleisner A; Cowan ML; Birnbaum E; Vogel JD
J Surg Oncol; 2019 Mar; 119(4):518-531. PubMed ID: 30637750
[TBL] [Abstract][Full Text] [Related]
8. Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Rusthoven CG; Koshy M; Sher DJ; Ney DE; Gaspar LE; Jones BL; Karam SD; Amini A; Ormond DR; Youssef AS; Kavanagh BD
JAMA Neurol; 2016 Jul; 73(7):821-8. PubMed ID: 27214765
[TBL] [Abstract][Full Text] [Related]
9. Utilization of hypofractionated radiation therapy in older glioblastoma patients.
Nead KT; Swisher-McClure S
J Geriatr Oncol; 2019 Jan; 10(1):155-158. PubMed ID: 30017732
[TBL] [Abstract][Full Text] [Related]
10. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base.
Huang J; Samson P; Perkins SM; Ansstas G; Chheda MG; DeWees TA; Tsien CI; Robinson CG; Campian JL
J Neurooncol; 2017 Feb; 131(3):593-601. PubMed ID: 27844308
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme.
Nunna RS; Khalid SI; Patel S; Sethi A; Behbahani M; Mehta AI; Adogwa O; Byrne RW
World Neurosurg; 2021 May; 149():e1026-e1037. PubMed ID: 33482415
[TBL] [Abstract][Full Text] [Related]
12. Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Chang-Halpenny CN; Yeh J; Lien WW
Perm J; 2015; 19(1):15-20. PubMed ID: 25663202
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
[TBL] [Abstract][Full Text] [Related]
14. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme.
Lipani JD; Jackson PS; Soltys SG; Sato K; Adler JR
Technol Cancer Res Treat; 2008 Jun; 7(3):249-55. PubMed ID: 18473497
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Arvold ND; Tanguturi SK; Aizer AA; Wen PY; Reardon DA; Lee EQ; Nayak L; Christianson LW; Horvath MC; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Alexander BM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):384-9. PubMed ID: 25841623
[TBL] [Abstract][Full Text] [Related]
16. Short-Term Outcomes and Cost-Effectiveness between Long-Course Chemoradiation and Short-Course Radiotherapy for Locally Advanced Rectal Cancer.
Cho MS; Bae HW; Chang JS; Yang SY; Kim TH; Koom WS; Shin SJ; Choi GS; Kim NK
Yonsei Med J; 2023 Jun; 64(6):395-403. PubMed ID: 37226566
[TBL] [Abstract][Full Text] [Related]
17. Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Perlow HK; Yaney A; Yang M; Klamer B; Matsui J; Raval RR; Blakaj DM; Arnett A; Beyer S; Elder JB; Ammirati M; Lonser R; Hardesty D; Ong S; Giglio P; Pillainayagam C; Goranovich J; Grecula J; Chakravarti A; Gondi V; Brown PD; Palmer JD
J Neurooncol; 2022 Jan; 156(2):399-406. PubMed ID: 35013838
[TBL] [Abstract][Full Text] [Related]
18. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
20. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
